HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia.

Abstract
T-cell prolymphocytic leukemia (T-PLL) is an aggressive tumor with leukemic presentation of mature T-lymphocytes. Here, we aimed at characterizing the initial events in the molecular pathogenesis of T-PLL and particularly, at determining the point in T-cell differentiation when the hallmark oncogenic events, that is, inv(14)(q11q32)/t(14;14)(q11;q32) and t(X;14)(q28;q11) occur. To this end, we mined whole genome and transcriptome sequencing data of 17 and 11 T-PLL cases, respectively. Mapping of the 14q32.1 locus breakpoints identified only TCL1A, which was moreover significantly overexpressed in T-PLL as compared to benign CD4+ and CD8+ T-cells, as the only common oncogenic target of aberrations. In cases with t(14;14), the breakpoints mapped telomeric and in cases with inv(14) centromeric or in the 3'-untranslated region of TCL1A. Regarding the T-cell receptor alpha (TRA) locus-TCL1A breakpoint junctions, all 17 breakpoints involved recombination signal sequences and 15 junctions contained nontemplated (N-) nucleotides. All T-PLL cases studied carried in-frame TRA rearrangements on the intact allele, which skewed significantly toward usage of distal/central TRAV/TRAJ gene segments as compared to the illegitimate TRA rearrangements. Our findings suggest that the oncogenic TRA-TCL1A/MTCP1 rearrangements in T-PLL occur during opening of the TRA locus, that is, during the progression from CD4+ immature single positive to early double positive thymocyte stage, just before physiologic TCL1A expression is silenced. The cell carrying such an oncogenic event continues maturation and rearranges the second TRA allele to achieve a functional T-cell receptor. Thereafter, it switches off RAG and DNTT expression in line with the mature T-cell phenotype at presentation of T-PLL.
AuthorsPaurnima Patil, Agata Cieslak, Stephan H Bernhart, Umut H Toprak, Rabea Wagener, Cristina López, Laura Wiehle, Susanne Bens, Janine Altmüller, Marek Franitza, Ingrid Scholz, Sandrine Jayne, Matthew J Ahearne, Annika Scheffold, Billy M C Jebaraj, Christof Schneider, Dolors Costa, Till Braun, Alexandra Schrader, Elias Campo, Martin J S Dyer, Peter Nürnberg, Jan Dürig, Patricia Johansson, Sebastian Böttcher, Matthias Schlesner, Marco Herling, Stephan Stilgenbauer, Elizabeth Macintyre, Reiner Siebert
JournalGenes, chromosomes & cancer (Genes Chromosomes Cancer) Vol. 59 Issue 4 Pg. 261-267 (04 2020) ISSN: 1098-2264 [Electronic] United States
PMID31677197 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2019 Wiley Periodicals, Inc.
Chemical References
  • Oncogene Proteins, Fusion
  • Receptors, Antigen, T-Cell
Topics
  • Alleles
  • Chromosome Aberrations
  • Gene Rearrangement
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study
  • Humans
  • Leukemia, Prolymphocytic, T-Cell (diagnosis, genetics)
  • Oncogene Proteins, Fusion (genetics)
  • Phenotype
  • Receptors, Antigen, T-Cell (genetics)
  • Transcriptome
  • Whole Genome Sequencing

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: